about
Targeting Cdc42 with the small molecule drug AZA197 suppresses primary colon cancer growth and prolongs survival in a preclinical mouse xenograft model by downregulation of PAK1 activityA Rac1/Cdc42 GTPase-specific small molecule inhibitor suppresses growth of primary human prostate cancer xenografts and prolongs survival in miceAssociation of the rs1346044 Polymorphism of the Werner Syndrome Gene RECQL2 with Increased Risk and Premature Onset of Breast Cancer.Colony-stimulating factor-1 transfection of myoblasts improves the repair of failing myocardium following autologous myoblast transplantation.Analysis of the rs10046 polymorphism of aromatase (CYP19) in premenopausal onset of human breast cancer.Modulating the tumor microenvironment with RNA interference as a cancer treatment strategy.PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.Egr-1 upregulates Siva-1 expression and induces cardiac fibroblast apoptosis.Inhibition of stromal PlGF suppresses the growth of prostate cancer xenografts.Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway.Toll-like receptor 3 signalling mediates angiogenic response upon shock wave treatment of ischaemic muscle.Frizzled2 signaling regulates growth of high-risk neuroblastomas by interfering with β-catenin-dependent and β-catenin-independent signaling pathways.Host CD147 blockade by small interfering RNAs suppresses growth of human colon cancer xenografts.Effects of azithromycin and tanomastat on experimental bronchiolitis obliterans.Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.Elevated CSF1 serum concentration predicts poor overall survival in women with early breast cancer
P50
Q28302802-B7BDB8D6-EEBF-400C-B57E-5A2E6E32B16FQ28533254-AF678C5F-FE59-49EF-A3FC-2106C5DB85CDQ36404268-D6AA26AC-A28F-4199-9C93-330859EEF70CQ37318863-0E8C090F-DB78-456B-A96A-1E7BA427221FQ37535511-E93B7F94-F8D9-48AA-8A60-167455CD7454Q38260607-E0A399E1-6D52-40F7-893B-CE3DC33093D4Q38743706-809D049D-083A-43B7-9F55-34A3143A6E5CQ39031870-92C37072-4471-480A-92B9-48D6E7F966E6Q39100169-56F5B6ED-D09E-4F31-94DB-B0BD1E9B6B02Q40174245-4640D71D-C928-4BB8-B287-823EEB1BDC44Q40202451-D33053CC-DE0D-454F-92EE-F4E97645ACE8Q40854205-858E6F9C-74F9-40D7-ABFB-53373B082DA7Q42812423-81432B7B-8358-4788-869C-588AFBB39836Q47761626-5E23AADF-1A75-4636-9BDA-4116E6C4BD78Q54707687-BEFB4003-7B3A-4B70-A0CD-98C911CC778CQ85703889-08219A2B-1A09-44FA-B946-20414634A1B9
P50
description
researcher ORCID ID = 0000-0002-0202-2364
@en
wetenschapper
@nl
name
Karin Zins
@ast
Karin Zins
@en
Karin Zins
@es
Karin Zins
@nl
type
label
Karin Zins
@ast
Karin Zins
@en
Karin Zins
@es
Karin Zins
@nl
prefLabel
Karin Zins
@ast
Karin Zins
@en
Karin Zins
@es
Karin Zins
@nl
P106
P21
P31
P496
0000-0002-0202-2364